News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the 'Investment in Innovation (In3) West' Conference


2/28/2008 9:27:58 AM

MOUNTAIN VIEW, Calif., Feb. 28 /PRNewswire/ -- Cardiva Medical, Inc., a privately held medical device company and developer of the Boomerang Catalyst(TM) System announces that it will present the highlights of the Boomerang Catalyst II System on February 29 at 9:20am at the Medtech Insight/Windhover Information's "Investment In Innovation (In3) West" medical technology investment and partnering conference held at The Venetian in Las Vegas, NV.

The Boomerang Catalyst II System builds on the success of its predecessor, the Boomerang Catalyst System, by adding an additional pro-coagulant to the proprietary hemostatic material of the Catalyst System. These generations are the first vascular closure devices to achieve final hemostasis on diagnostic patients in the catheterization lab leaving absolutely nothing behind in the patient, thereby eliminating a major source of complications, device failures, and re-access challenges. Additionally, clinical results presented in October 2007 at the TCT meeting in Washington D.C. showed that patients required statistically significantly less bed rest than patients utilizing the gold standard of manual compression for closure of the arterial access site.

To date, the family of Boomerang devices has been used in more than 100,000 percutaneous catheterization procedures in the U.S. During these procedures, a catheter is threaded through the femoral artery to the site of vascular disease (most common is in the heart), where diagnosis and/or treatment (such as stenting or angioplasty) can be performed. Traditionally, doctors have used two primary methods to close the femoral artery puncture site: direct manual compression over the puncture site or one of the various implantable vascular closure devices, which use materials (such as collagen, sutures, or staples) to create a physical seal of the puncture site.

"The Catalyst II device promises to build upon the already impressive clinical achievements of its predecessor," commented Ron Smalling, MD, Interventional Cardiologist, St. John's, Joplin, MO. Dr. Smalling, who is a member of Cardiva's Medical Advisory Board, continued, "The ability to ambulate even faster than its predecessor while not leaving any material in the body is a significant advantage for patients, the hospital and the staff."

About Cardiva Medical, Inc.

Founded in July 2002, and headquartered in Mountain View, Calif., Cardiva Medical, Inc. is a privately held medical company focused on developing and commercializing devices which close the vascular access site with unsurpassed safety and ease-of-use. Cardiva's first product, the Boomerang Wire System, was approved in EU countries and in the US in 2004. Cardiva's second-generation product, the Boomerang Catalyst System, was approved in March 2007 and launched in July 2007. The enhanced Boomerang Catalyst, trade named as "Boomerang Catalyst II System" received 510(K) clearance in September 2007 and launched in January 2008. Cardiva was selected by Frost & Sullivan as the recipient of the 2006 Frost & Sullivan Award for Entrepreneurial Company in the U.S. angioplasty and vascular closure devices market. For additional information about Cardiva Medical, Inc. see our website at http://www.cardivamedical.com.

Cardiva, Boomerang and Boomerang Catalyst System are trademarks/registered trademarks of Cardiva Medical, Inc.

glenn_foy@cardivamedical.com

CONTACT: Glenn Foy, President of Cardiva Medical, Inc., +1-650-964-8900,
ext. 215, Fax, +1-650-964-8911, glenn_foy@cardivamedical.com

Web site: http://www.cardivamedical.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES